Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085630 | 0.91 | HTR2A (0.39) | POLBGAAGFERALDH1A1HTR2A | |
| SCHEMBL13085639 | 0.84 | ALDH1A1 (0.33) | POLBGAAGFERALDH1A1MEN1 | |
| SCHEMBL17344742 | 0.82 | — | — | |
| SCHEMBL13998946 | 0.82 | HTR2A (0.35) | POLBALDH1A1ACHEHTR2AHTR2C | |
| SCHEMBL13085640 | 0.80 | ALDH1A1 (0.37) | POLBGAAGFERALDH1A1HTR2A | |
| SCHEMBL13085732 | 0.77 | ACHE (0.35) | POLBALDH1A1ACHE | |
| SCHEMBL10289183 | 0.76 | CYP3A4 (0.34) | POLBALDH1A1ACHEHTR2AHTR2C | |
| SCHEMBL1621090 | 0.76 | ALDH1A1 (0.40) | POLBGAAALDH1A1MEN1KMT2A | |
| SCHEMBL13241848 | 0.76 | CYP1A2 (0.30) | — | |
| SCHEMBL22016468 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | POLB 4527/4885GAA 2310/4885GFER 2253/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | POLB 2269/4885GAA 3903/4885GFER 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.